Sitagliptin does not appear to cause cardiovascular problems
Metadata[+] Show full item record
This randomized, double-blind, noninferiority trial compared sitagliptin (n=7,332) with placebo (n=7,339) in patients older than 50 years. All patients had type 2 diabetes mellitus (with an average HbA1C between 6.5% and 8% at the time of enrollment) and had a history of cardiovascular disease. Patients received sitagliptin 100 mg tablets or matched placebo daily for 3 years with the use of other antihyperglycemic agents.
Evidence-Based Practice 19, no. 8 (2016): 4